MedTrace Logo

Prognostic Markers for a Better Follow-up in Head and Neck Cancer.

NCT06094985 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-03-05

No results posted yet for this study

Summary

To identify tumor specific DNA mutations and aberrations and to follow these in blood over time to predict treatment response/survival and secondly to correlate presence of these markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological findings and to tumor stage.

Conditions

Interventions

GENETIC

DNA exome sequencing of tumor and blood

A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.

Sponsors & Collaborators

Principal Investigators

  • Anders Näsman, MD PhD · Karolinska institutet and Karolinska Universitetssjukhuset

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-12
Primary Completion
2024-05-31
Completion
2026-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06094985 on ClinicalTrials.gov